A Multiple-Dose, Open-Label Pharmakokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes
Phase of Trial: Phase I
Latest Information Update: 14 Nov 2016
At a glance
- Drugs Bardoxolone methyl (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- 14 Nov 2016 Results published in the Media Release
- 01 Nov 2012 Planned End Date changed from 1 Sep 2012 to 1 Oct 2013 as reported by ClinicalTrials.gov.
- 01 Nov 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.